SUNESIS PHARMACEUTICALS INC·3

Feb 25, 6:09 PM ET

aMoon 2 Fund Limited Partnership 3

3 · SUNESIS PHARMACEUTICALS INC · Filed Feb 25, 2021

Insider Transaction Report

Form 3
Period: 2021-02-24
Holdings
  • Common Stock

    (indirect: See Footnote)
    2,032,865
  • Common Stock

    5,359,372
Footnotes (2)
  • [F1]The reported shares are held of record by aMoon 2 Fund, Limited Partnership ("aMoon 2 Fund"). aMoon 2 Fund G.P. Limited Partnership ("aMoon 2 Fund G.P.") is the sole General Partner of aMoon 2 Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon 2 Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon 2 Fund. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon 2 Fund except to the extent of its or his pecuniary interest therein, if any.
  • [F2]The reported shares are held of record by aMoon - VRCT SPV Limited Partnership ("aMoon - VRCT"). aMoon 2 Fund G.P. is the sole General Partner of aMoon - VRCT and aMoon General Partner is the sole General Partner of aMoon 2 Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon - VRCT. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon - VRCT except to the extent of its or his pecuniary interest therein, if any.

Documents

1 file
  • 3
    doc3.xmlPrimary

    FORM 3 SUBMISSION